Augtyro for ROS1-positive non-small cell lung cancer
Quick answer: Augtyro is used for ROS1-positive non-small cell lung cancer as part of a ros1/ntrk tyrosine kinase inhibitor treatment regimen. Repotrectinib selectively inhibits ROS1 and TRKA/B/C kinases including resistance mutations The specific dosing for ROS1-positive non-small cell lung cancer is determined by your prescriber based on individual factors.
Why is Augtyro used for ROS1-positive non-small cell lung cancer?
Augtyro belongs to the ROS1/NTRK tyrosine kinase inhibitor class. Repotrectinib selectively inhibits ROS1 and TRKA/B/C kinases including resistance mutations This action makes it useful for treating or managing ROS1-positive non-small cell lung cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Augtyro is the right choice for a specific patient depends on the type and severity of ROS1-positive non-small cell lung cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for ROS1-positive non-small cell lung cancer
Common adult dosing range: 160 mg once daily for 14 days then 160 mg twice daily. The actual dose for ROS1-positive non-small cell lung cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Augtyro medicine page.
What to expect
Augtyro treatment for ROS1-positive non-small cell lung cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on ROS1-positive non-small cell lung cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Augtyro is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all ROS1/NTRK tyrosine kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Augtyro
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Augtyro full prescribing information · All ROS1/NTRK tyrosine kinase inhibitor alternatives
Frequently asked questions
How effective is Augtyro for ROS1-positive non-small cell lung cancer?
Effectiveness varies by individual response, dose, and severity. Augtyro is one of several treatment options for ROS1-positive non-small cell lung cancer, supported by clinical evidence within the ros1/ntrk tyrosine kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Augtyro for ROS1-positive non-small cell lung cancer?
Treatment duration depends on the nature of ROS1-positive non-small cell lung cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Augtyro when used for ROS1-positive non-small cell lung cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Augtyro for ROS1-positive non-small cell lung cancer?
Yes. Multiple medicines and non-drug options exist for ROS1-positive non-small cell lung cancer. Alternatives within the ros1/ntrk tyrosine kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.